The first echinocandin: caspofungin: Das erste Echinocandin: Caspofungin
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of conventional amphotericin B, its lipid‐based formulations, and/or itraconazole. It is given as a 70 mg loading dose and a 50 mg daily maintainance dose as a one hour infusion. Due to low intestinal absorption an oral formulation has not been developed. Caspofungin is active against Candida spp. and Aspergillus spp. by inhibition the synthesis of β‐(1,3)‐D‐glucan, a cell wall component. The drug is inactive against Cryptococcus spp., Fusarium spp., Trichosporon spp., Rhizopus spp., and Pseudoallescheria spp. In invasive aspergillosis caspofungin resulted in higher response rates compared to a historic control under standard therapy. Efficacy data on persistently febrile neutropenic patients are pending. In several multicenter randomised double blind trials on candida infections caspofungin proved to be at least non‐inferior to standard therapies. Reports of combination therapy or highly effective antifungal treatment (HEAT) in limited patient numbers are promising. New trials of combination therapy are warranted. Zusammenfassung. Caspofungin ist das erste Antimykotikum aus der Klasse der Echinocandine. Es ist in den USA und in Europa zugelassen zur Therapie invasiver Aspergillosen erwachsener Patienten, die auf eine Standardtherapie nicht ansprechen oder diese nicht vertragen. Caspofungin wird am ersten Tag mit 70 mg dosiert und danach mit einer Erhaltungsdosis von 50 mg als einstündige Infusion verabreicht. Wegen seiner geringen enteralen Resorption ist eine orale Formulierung nicht entwickelt worden. Caspofungin ist wirksam gegen Candida spp. und Aspergillus spp. durch die Inhibition der Synthese des β‐(1,3)‐D‐Glucans, das ein Bestandteil der Zellwand ist. Die Substanz ist unwirksam gegenüber Cryptococcus spp., Fusarium spp., Trichosporon spp., Rhizopus spp., und Pseudoallescheria spp. In der Therapie der invasiven Aspergillose war Caspofungin effektiver als Standardtherapien in einem historischen Vergleichskollektiv. Daten zur Effektivität persistierend febriler neutropenischer Patienten werden erwartet. In einigen randomisierten multizentrischen doppel‐blinden Studien zu Candida‐Infektionen zeigte sich Caspofungin zumindest als nicht‐unterlegen im Vergleich zu Standardtherapien. Berichte über Kombinationstherapien, die sog. hocheffektive antimykotische Therapie (HEAT) begrenzter Patientenzahlen sind vielversprechend. Weiter führende Kombinationsstudien sind erforderlich.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254
Safety and tolerability of caspofungin acetate in the treatment of fungal infections
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.01004.x · Cited by 148
Cited by
Current Knowledge of Trichosporon spp. and Trichosporonosis
Colombo, A. L., Padovan, A. C. B., & Chaves, G. M. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00003-11 · Cited by 545
(2003) · PubMed · Cited by 240
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
“Threemajor classes of antifungal agents are available to treat IPA: triazoles, echinocandins, and polyenes [74,75].”
Background
Metadata
- Authors
- Cornely, O. A., Schmitz, K., & Aisenbrey, S.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2002-04
- Volume
- 45
- Issue
- S3
- Pages
- 56-60
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W2147459045
- Cited by
- 53
- References
- 3
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.